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Abstract
Background: Peritoneal dialysis (PD) is a form of therapy for end-stage kidney disease (ESKD), and peritonitis is a
known complication. Mycobacterium (M) species associated peritonitis in PD patients is uncommon. Our experience
of managing PD associated peritonitis caused by M abscessus in a middle-aged man with ESKD due to focal
segmental glomerulosclerosis is shared in this article with a review of the literature on this condition.
Case presentation: A 49-year old man presented to our unit with symptoms of peritonitis and cloudy PD effluent.
Initial analysis of PD fluid showed Gram stain was negative, with no organism grown. Empirical PD peritonitis
treatment with intra-peritoneal antibiotics did not improve his symptoms and he required intravenous antibiotics,
PD catheter removal and a switch to haemodialysis. Cultures of the PD fluid later grew M abscessus, and the
antibiotic regimen was changed appropriately, leading to clinical improvement.
Conclusion: M abscessus associated peritonitis in PD patients is rare. It needs to be borne in mind when clinical
improvement is not seen with standard broad-spectrum antibiotics, especially in situations where the PD fluid is
initially deemed to be culture negative. PD fluid samples should be sent for acid-fast bacillus and if detected,
should be further analysed with genome-wide sequencing to confirm the species of the Mycobacterium. Prompt
removal of the catheter with peritoneal washout is critical for clinical improvement.
Keywords: Peritoneal dialysis, Catheter, Peritonitis, Mycobacterium abscessus
Background
Peritoneal dialysis is used for managing end-stage kidney
disease (ESKD). It requires access to the peritoneal space
by way of a percutaneous tunnelled dialysis catheter. In-
fective complications of peritoneal dialysis (PD) include
catheter exit-site infection (ESI), catheter tunnel infec-
tion (TI) and peritonitis. Peritonitis can be particularly
severe and can lead to PD failure and discontinuation of
PD. [1] Early recognition of infections, prompt microbio-
logical diagnosis, and establishing appropriate treatment
are therefore essential. An essential factor that deter-
mines a successful outcome in such cases is anti-
microbial susceptibility testing to guide appropriate
therapy. PD related peritonitis is most commonly caused
by gram-positive aerobes such as coagulase-negative
Staphylococci and Staphylococcus aureus, or gram-
negative aerobes such as Pseudomonas aeruginosa [2].
Reports of PD related peritonitis caused by Mycobacter-
ium species are relatively rare, although their incidence
© The Author(s). 2020 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License,
which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give
appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if
changes were made. The images or other third party material in this article are included in the article's Creative Commons
licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons
licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain
permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the
data made available in this article, unless otherwise stated in a credit line to the data.
* Correspondence: Nephr0nite@gmail.com
1South West Thames Renal & Transplantation Unit, Epsom & St Helier
University Hospitals NHS Trust, Wrythe Lane, Carshalton, Surrey SM5 1AA, UK
Full list of author information is available at the end of the article
Jheeta et al. BMC Nephrology          (2020) 21:491 
https://doi.org/10.1186/s12882-020-02146-4
has been well documented [3, 4]. Nontuberculous myco-
bacteria (NTM) are members of the genus Mycobacter-
ium but are significantly different from other members
of the same genus, e.g., M.tuberculosis and M.leprae.
NTM related PD peritonitis is emerging as a diagnostic
and therapeutic challenge in the management of PD
peritonitis, with comparatively higher rates of PD cath-
eter loss and PD failure compared to other organisms
[5]. Consensus on the management of NTM related PD
peritonitis does not currently exist, possibly because of
the paucity of reported cases. We describe what is to our
knowledge the first reported case in the UK of PD
related peritonitis secondary to the NTM species Myco-
bacterium abscessus.
Case presentation
A 49-year-old male of Afro-Caribbean origin with a
background of hypertension, type 2 diabetes mellitus,
high body mass index of 40 and ESKD secondary to
focal and segmental glomerulosclerosis (FSGS) diag-
nosed in 2007 and received only 1 month of corticoste-
roids. He presented to our PD unit with mild abdominal
discomfort and cloudy PD effluent in July 2019. He had
been on PD for 4 years and had experienced one previ-
ous episode of PD peritonitis caused by Staphylococcus
aureus requiring catheter replacement 2 years ago. The
PD regimen consisted of automated peritoneal dialysis
[APD] of 8.5 h duration with 5 cycles of 3 l fills. The di-
alysate fluid consisted of 1.36% glucose concentration of
10 l and 2.27% glucose concentration of 5 l with extra-
neal (Icodextrin 7.5%) solution as a last fill of 1.7 l. He
also received an Opti exchange of 2.0 l of 1.36% solution
in the evenings.
He was clinically and haemodynamically stable with
mild abdominal discomfort as his symptom. Serum in-
flammatory markers showed a white cell count [WCC]
of 6.0 × 106/L and a C-reactive protein [CRP] of 80.7
mg/L (normal range < 5mg/L). Microscopy of the PD
fluid showed a WCC of 155 x 106cells/L and a total eo-
sinophil count of 1 × 106 cells/L, but the Gram stain was
negative. Empirical broad-spectrum intra-peritoneal an-
tibiotics (Vancomycin and Gentamicin) were com-
menced. On day 5, he developed worsening abdominal
pain. On examination, his blood pressure was 158/100
mmHg; heart rate 90/min, temperature 37.5 °C. His ab-
domen was tender on palpation. There was no evidence
of PD catheter exit site infection or any tunnel infection.
The CRP was 456.9 mg/L, and WCC was 12.3 × 106/L.
He was admitted to the renal unit and treatment was esca-
lated to intravenous Gentamicin and Vancomycin, and
subsequently to intravenous Meropenem on day 7 in view
of persistent symptoms and raised inflammatory markers.
He underwent rapid PD fluid exchanges to help relieve ab-
dominal pain. On day 8, his CRP was 534mg/L, WCC
was 20.5 × 106/L with a temperature of 39.8 °C. He under-
went emergency surgical PD catheter removal with peri-
toneal washout. Intra-operative findings did not reveal any
bowel perforation. A haemodialysis catheter was inserted,
and regular haemodialysis (HD) was commenced. On day
8, acid-fast bacilli [AFB] were grown from the PD fluid
sample, which was confirmed by the National Mycobac-
terium Reference Laboratory through whole-genome se-
quencing to be Mycobacterium abscessus. In view of this,
he was commenced on quadruple therapy with intra-
venous Amikacin, Clarithromycin, Tigecycline and
Imipenem with cilastatin. He developed new QTc
prolongation on the electrocardiogram (ECG) on day
16, which was attributed to Clarithromycin, so this
was therefore discontinued. Furthermore, he developed
acute hepatic impairment which resolved following
cessation of Tigecycline on day 26.
He remained clinically well on dual therapy with intra-
venous Amikacin and Imipenem and was discharged on
day 35 (Fig. 1). A peripherally inserted central venous
catheter was placed, to facilitate daily intravenous antibi-
otics as an outpatient. He continued on antibiotics for a
total of 5 months. Linezolid was added during the last 6
weeks of therapy. He had a regular review by the Audiol-
ogists, but in spite of close monitoring to maintain the
Amikacin levels within the therapeutic range, he has
sustained a degree of sensorineural hearing loss.
Discussion and conclusion
M.abscessus is a nontuberculous mycobacterium (NTM).
It is one of the most clinically relevant, rapidly growing
mycobacteria, which are environmental organisms that usu-
ally grow in culture within 1 week. M. abscessus has been
frequently isolated from water, soil, domestic and wild ani-
mals [6]. Although not highly virulent, M.abscessus is
known to cause disseminated infection in immunocom-
promised hosts, and bacteraemia can occur in the context
of dialysis catheter use [7]. It is a well-documented cause of
pulmonary infection in patients with structural lung disease
such as cystic fibrosis, and can cause skin and soft tissue
infections in hospitalised post-surgical patients [8, 9].
Diagnosis
The diagnosis of NTM and M.abscessus PD peritonitis
can be challenging. NTM can cause culture-negative in-
fection, and it is interesting to note that in 4 out of 16
reported cases, the development of PD peritonitis was
preceded by catheter replacement for the management
of what was deemed to be culture-negative ESI or TI [3,
10, 11]. Clinicians should, therefore be vigilant with
regards to possible NTM infection in patients with
culture-negative PD peritonitis, particularly in the con-
text of non-responsiveness to standard anti-microbial
therapy [5, 12].
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Our patient was diabetic and on PD for his kidney fail-
ure. The presence of end-stage renal failure (ESRF) is as-
sociated with impairment of the innate and adaptive
immune system [13]. Diabetes mellitus was present in
27.5% of cases of NTM related PD peritonitis in one sys-
tematic review, suggesting that metabolic disease may
pre-dispose to NTM infection [5]. M.abscessus has a
predisposition to create biofilms, colonise and infect
catheters [7]. Consequently, all previously documented
cases of M.abscessus PD peritonitis have required cath-
eter removal for effective source control (Table 1). The
intrinsic resistance of M.abscessus to classical anti-
tuberculous drugs as well as most other available broad-
spectrum antibiotics limits the choice of options for
therapy [20] and poses a significant challenge with
regards to treatment.
A systematic review of 57 cases of NTM PD peritonitis
found that the time from onset of symptoms to the initi-
ation of appropriate treatment was 4 weeks [5]. This
delay is multi-factorial. Firstly, the available data do not
demonstrate any factor unique to M.abscessus PD peri-
tonitis compared with more common organisms. The
symptoms and signs are indistinguishable from conven-
tional PD peritonitis or tuberculous peritonitis [4, 21].
All cases of M.abscessus PD peritonitis first received em-
pirical antibiotics and in one case, subsequently received
anti-tuberculous therapy following a positive acid-fast
bacillus (AFB) stain [22]. Secondly, the utility of AFB
staining in such cases is debatable, as the sensitivity of
this test is not high enough [23]. In one particular study,
AFB staining was positive in only four out of 10 cases of
M.abscessus peritonitis [4]. Most centres do not perform
AFB staining routinely as it does not distinguish between
tuberculous mycobacteria and NTM, thus providing no
further information regarding anti-microbial sensitivities
[24, 25]. As a consequence, the diagnosis is reliant on
bacterial culture alone, which leads to delays in the initi-
ation of appropriate treatment and may likely result in
worse outcome in such cases [26].
Treatment
The management of M.abscessus PD peritonitis is com-
plex. Catheter removal appears to be essential to recov-
ery in the acute setting, with long term management
reliant on anti-microbial therapy [12, 17]. M.abscessus is
a multi-drug resistant organism, and as a consequence,
the antibiotic choices are limited. One report investi-
gated resistance and susceptibility criteria of M.abscessus
in various published cases and showed that resistance
rates for Quinolones, Doxycycline and Imipenem, were
considerably high, while resistance rates for Cefoxitin
(15.1%) and Amikacin (7.7%) were low. Clarithromycin
showed variable resistance rates ranging from 0 to 38%.
As a consequence, treatment should be based on the
susceptibility profile of the bacterium isolated from
individual patients [18].
It has been recommended that non-pulmonary
M.abscessus infection should be treated for between 4
and 6months [27]. There is no consensus, however, for
the optimal duration of the treatment for M.abscessus
PD peritonitis and this is reflected in the variability of
treatment regimens observed in the reported cases,
where treatment duration ranged from 7 weeks to 28
weeks with a variety of drug combinations used based
on individual sensitivities.
The challenges posed by the administration of long-
term antibiotics should also be recognised. In our case,
quadruple therapy was not tolerated due to the develop-
ment of hepatic impairment with Tigecycline and QTc
prolongation with Clarithromycin. Similar complications
were observed in previous cases with Amikacin (sensori-
neural hearing loss) and Clarithromycin (hepatic impair-
ment) [12]. The optimal duration of anti-microbial
therapy is unclear at present but is likely to be at least 4
months [27].
Overall, outcomes from M.abscessus PD peritonitis ap-
pear to be worse than for conventional organisms. A 10-
year retrospective cohort study of PD peritonitis in an
Australian population found that the risk of catheter re-
moval varied between < 20 to > 40% depending on the
causative organism [17]. The risk of changing over to
HD was estimated to be between 5 to 20% [1]. In previ-
ously reported cases of M.abscessus PD peritonitis, 100%
of patients were converted to HD [6]. In only two of
these cases were the patients successfully converted back
to PD, suggesting that the risk of PD failure is higher
with M.abscessus infection compared with conventional
organisms.
Fig. 1 Timeline of inpatient stay
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In summary, we present, to our knowledge, the first
reported case of M.abscessus PD peritonitis in the
United Kingdom. It was managed with catheter removal,
a prolonged course of intravenous broad-spectrum anti-
biotics and conversion to HD. Clinicians should have a
high index of suspicion of M.abscessus in cases of non-
resolving PD related infections, or culture-negative peri-
tonitis. Catheter removal appears to be essential for clin-
ical recovery, and the switch to HD may be permanent.
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